The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
Last update: 13/05/2022
There are currently 26 open trials
Cilta-cel CAR-T cell therapy for newly diagnosed myeloma patients
Cilta-cel (Ciltacabtagene autoleucel)
This trial is investigating how cilta-cel, a type of treatment known as chimeric antigen receptor T cell (CAR T Cell) therapy, compares to the combination of lenalidomide (Revlimid®) and dexamethasone for the treatment of newly diagnosed myeloma patients.
University College Hospital, London;
King's College Hospital, London
Who can enter the study?:
Newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplantation (HDT-SCT).
All patients will receive bortezomib (Velcade®), lenalidomide, and dexamethasone (VRd) regimen for six cycles before randomization. Patients will then be randomly allocated into Group A or Group B.
Patients in Group A will receive two more cycles of VRd. Group A will then receive lenalidomide and dexamethasone (Rd) maintenance therapy until there are signs of disease progression or it is discontinued for other reasons.
Patients in Group B will undergo leukapheresis (T cell harvest) after six cycles of VRd. The harvested T cells are then modified to become the CAR-T cell treatment. Patients will then receive two more cycles of VRd. Patients will then receive the cilta-cel treatment by intravenous infusion (into a vein).
Patients will be required to regularly fill in surveys, and attend outpatient clinics for regular check-ups and blood tests.
Patients will be followed up for up to 12 years and 5 months.
(for Medical Professionals):
A randomised, open-label, phase III clinical trial evaluating the safety and efficacy of cilta-cel compared to lenalidomide and dexamethasone (Rd) maintenance therapy for the treatment of newly diagnosed myeloma patients, who are not eligible for HDT-SCT.